



## Liquidia Corporation to Present at the 2024 Jefferies Global Healthcare Conference

May 29, 2024

MORRISVILLE, N.C., May 29, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that Michael Kasetta, chief operating officer and chief financial officer, will provide an update on the company's business during a fireside chat at the 2024 Jefferies Global Healthcare Conference on Wednesday June 5, 2024, beginning at 9:00 a.m. ET, in New York City, NY.

Access to a webcast will be available to investors and other interested parties by accessing Liquidia's website at <https://liquidia.com/investors/events-and-presentations>.

An archived, recorded version of the presentation will be available on Liquidia's website for at least 30 days following the event.

### About Liquidia Corporation

Liquidia Corporation is a biopharmaceutical company focused on the development and commercialization of products in pulmonary hypertension and other applications of its PRINT<sup>®</sup> Technology. The company operates through its two wholly owned subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Liquidia Technologies has developed YUTREPIA<sup>™</sup> (treprostinil) inhalation powder for the treatment of PAH and PH-ILD. Liquidia Technologies is also developing L606, an investigational liposomal formulation of treprostinil administered twice-daily with a next-generation nebulizer, for use in North America. Liquidia PAH provides the commercialization for pharmaceutical products to treat pulmonary disease, such as generic Treprostinil Injection. For more information, please visit [www.liquidia.com](http://www.liquidia.com).

### Contact Information

#### Investors:

Jason Adair  
Chief Business Officer  
919.328.4350  
[jason.adair@liquidia.com](mailto:jason.adair@liquidia.com)

#### Media:

Patrick Wallace  
Director, Corporate Communications  
919.328.4383  
[patrick.wallace@liquidia.com](mailto:patrick.wallace@liquidia.com)



Source: Liquidia Corporation